当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Establishment and characterization of the tumors of chronic lymphocytic leukemia cell line in nude and SCID mice.

Establishment and characterization of the tumors of chronic lymphocytic leukemia cell line in nude and SCID mice.

Abstract：

:A new cell line, designated MO1043, was established from the peripheral blood (PB) of a patient with B-cell chronic lymphocytic leukemia (CLL). Both the PB leukemia cells and MO1043 were found to have an abnormal cytogenetic marker of trisomy 12, the most common cytogenetic abnormality in CLL. In addition, both the PB cells and MO1043 expressed a cell surface phenotype of typical B-CLLs. The MO1043 was efficiently transplanted into X-irradiated athymic nude mice by i.p. inoculation after it was subjected to serial passages in new born (1 week old) and irradiated adult nude mice. The tumor of a CLL cell line (termed CLL tumor) was also generated in the nude mice by s.c. inoculation of the cells. The MO1043 was inoculated i.p. into mice with severe combined immunodeficiency (SCID) which had not been subject to any preconditionings. The CLL tumor in the non-conditioned SCID mice was disseminated to various tissues in a manner more analogous to CLL tumors in patients as compared with nude mice, where the CLL tumors were not as widely disseminated. At each of four different tumor doses, i.e. 2 x 10(6), 6 x 10(6), 1.8 x 10(7) and 5.4 +/- 10(7) cells of MO1043, the transplantability was 100%. Titration experiments revealed a reciprocal relationship between survival and the number of tumor cells inoculated. FACS analysis showed that several cell surface markers of the parental MO1043 were maintained in CLL tumors from nude and SCID mice. Fluorescence in situ hybridization with novel DNA probes demonstrated that CLL tumors of both nude and SCID mice maintained trisomy 12. The CLL tumor models developed here, particularly the SCID mouse model, may be very useful for therapeutic studies of CLL.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Kawata A,Han T,Dadey B,Weier HU,Okazaki M,Yokota S,Fukiage T,Xiao H,Block AM,Barcos M

doi

10.1016/0145-2126(93)90154-d

subject

Has Abstract,Author List Incomplete

pub_date

1993-10-01 00:00:00

pages

883-94

issue

10

eissn

0145-2126

issn

1873-5835

journal_volume

17

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Serum erythropoietin concentrations in patients with myelodysplastic syndromes.

    abstract：:Medullary dyserythropoiesis with reduced production of erythrocytes is an early and consistent feature of myelodysplastic syndromes (MDS). The mechanism underlying the disturbed red cell proliferation and maturation is presently unknown. In order to study the role of erythropoietic growth factors, we determined by rad...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(91)90025-o

    authors： Aul C,Arning M,Runde V,Schneider W

    更新日期：1991-01-01 00:00:00

  • Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.

    abstract：:The aim of this study was to evaluate effect of c-KIT mutations on RUNX1/RUNX1T1 fusion transcript expression in patients with t(8;21)-positive AML. Fifty patients diagnosed with t(8;21)-positive AML for recent 10 years were enrolled. Patients with c-KIT mutations tended to achieve a greater than 3-log reduction in RU...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2013.02.010

    authors： Park SH,Chi HS,Cho YU,Jang S,Park CJ

    更新日期：2013-07-01 00:00:00

  • Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia.

    abstract：:We examined polymorphisms of glutathione S-transferase (GST) genes in 159 Japanese patients with myelodysplasia and compared the incidence with that in 43 normal individuals to clarify their pathogenetic significance in myelodysplasia. In individuals with the GSTT1 null genotype, the odds ratios for disease risk were ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(99)00119-8

    authors： Sasai Y,Horiike S,Misawa S,Kaneko H,Kobayashi M,Fujii H,Kashima K,Taniwaki M

    更新日期：1999-11-01 00:00:00

  • Human interleukin 4 regulates the phenotype of lymphocytes generated during mixed lymphocyte culture and inhibits the IL-2-induced development of LAK function in normal and leukaemic cells.

    abstract：:This study examined the immunoregulatory role of recombinant interleukin 4 (IL-4), also known as B-cell stimulating factor 1, on the generation of cytotoxic effector cells from normal and leukaemic human blood mononuclear cells. When tested on cells from normal individuals, the addition of IL-4 to mixed lymphocyte cul...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(89)90066-0

    authors： Jin BQ,Lopez AF,Gillis S,Juttner CA,Vadas MA,Burns GF

    更新日期：1989-01-01 00:00:00

  • Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

    abstract：:Blastic transformation of myeloproliferative neoplasms (MPN) is still poorly understood. We describe a cohort of 23 Roswell Park Cancer Institute (RPCI) patients and 89 additional cases from the English literature for whom biologic features were described. We initially compared our 23 patients to the 89 cases from the...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2010.07.031

    authors： Noor SJ,Tan W,Wilding GE,Ford LA,Barcos M,Sait SN,Block AW,Thompson JE,Wang ES,Wetzler M

    更新日期：2011-05-01 00:00:00

  • Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG.

    abstract：:Total body irradiation (TBI) has traditionally been used in the conditioning regimen for allogenetic hematopoietic stem cell transplantation (alloHCT) from an unrelated donor (u-HCT). However, patients are increasingly receiving a fludarabine-based conditioning regimen without TBI, as it seemed less toxic than TBI. We...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2014.01.002

    authors： Kim H,Lee KH,Kim I,Sohn SK,Jung CW,Joo YD,Kim SH,Kim BS,Choi JH,Kwak JY,Kim MK,Bae SH,Shin HJ,Won JH,Lee WS,Oh S,Kim HJ,Park JH,Korean Society of Blood and Marrow Transplantation.

    更新日期：2014-07-01 00:00:00

  • Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-N-dimethylsphingosine.

    abstract：:We evaluated the cytotoxicity of dimethylsphingosine (DMS) against four human leukemia cell lines: two acute (HL60 and a multi-drug resistance MDR-positive derivative HL60-dox) and two blast crisis chronic myelogenous leukemias (JFP1, from a treatment refractory patient and K562), and against blasts isolated from 11 l...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(01)00129-1

    authors： Jendiroba DB,Klostergaard J,Keyhani A,Pagliaro L,Freireich EJ

    更新日期：2002-03-01 00:00:00

  • Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cells.

    abstract：:Osteogenic growth peptide (OGP) is a peptide exerting regulatory effects on the bone and on bone marrow. The carboxy-terminal pentapeptide (OGP10-14) is the biologically active portion of OGP. We evaluated OGP10-14 hematopoietic activity performing colony-forming tests on human stem cells derived by bone marrow, perip...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(02)00008-5

    authors： Fazzi R,Galimberti S,Testi R,Pacini S,Trasciatti S,Rosini S,Petrini M

    更新日期：2002-09-01 00:00:00

  • Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities.

    abstract：:The prognostic impact of combined NPM1+/FLT3- genotype is not well defined in elderly patients with acute myeloid leukemia (AML), and in the setting of different treatments, such as cytotoxic chemotherapy (Chemo), hematopoietic cell transplantation (HCT), or hypomethylating agents (HMA). Eighty-two elderly (age >60 ye...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2015.09.001

    authors： Hefazi M,Siddiqui M,Patnaik M,Wolanskyj A,Alkhateeb H,Zblewski D,Elliott M,Hogan W,Litzow M,Al-Kali A

    更新日期：2015-09-03 00:00:00

  • A role for mitochondrial DNA in the pathogenesis of radiation-induced myelodysplasia and secondary leukemia.

    abstract：:The onset of acute myeloid leukemia following ionizing radiation or alkylating agent exposure is antedated months to years by the development of 'preleukemia', or secondary myelodysplastic syndrome (sMDS). Mitochondrial abnormalities induced by chloramphenicol and clonal deletions of mitochondrial DNA (mt DNA) in the ...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/0145-2126(93)90036-k

    authors： Hatfill SJ,La Cock CJ,Laubscher R,Downing TG,Kirby R

    更新日期：1993-11-01 00:00:00

  • Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

    abstract：:A novel bone biopsy technique was used to generate a robust stromal cell system to study how stroma modulates CLL B-cell apoptosis and how the leukemic cell-stromal interaction influences secretion of vascular factors. Marrow stromal elements (MSE) rescued CLL B-cells from both spontaneous and drug induced apoptosis, ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.11.024

    authors： Kay NE,Shanafelt TD,Strege AK,Lee YK,Bone ND,Raza A

    更新日期：2007-07-01 00:00:00

  • Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.

    abstract：BACKGROUND:Most patients with myelodysplastic syndromes (MDS) require transfusions at the risk of iron overload and associated organ damage, and death. Emerging evidence indicates that iron chelation therapy (ICT) could reduce mortality and improve survival in transfusion-dependent MDS patients, especially those classi...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2014.02.003

    authors： Delforge M,Selleslag D,Beguin Y,Triffet A,Mineur P,Theunissen K,Graux C,Trullemans F,Boulet D,Van Eygen K,Noens L,Van Steenweghen S,Lemmens J,Pierre P,D'hondt R,Ferrant A,Deeren D,Van De Velde A,Wynendaele W,André M

    更新日期：2014-05-01 00:00:00

  • Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells.

    abstract：:Bcr-Abl tyrosine kinase inhibitor induces apoptosis and erythroid differentiation of K562 cells. During this erythroid differentiation, c-Myc and cyclin D1 transcripts are transiently downregulated. Accordingly, we studied the effect of cyclin D1 overexpression on erythroid differentiation. After treatment with 250 nM...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2003.10.022

    authors： Kawano T,Horiguchi-Yamada J,Saito S,Iwase S,Furukawa Y,Kano Y,Yamada H

    更新日期：2004-06-01 00:00:00

  • Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid.

    abstract：:All-trans-retinoic acid (ATRA) has been proven active against a range of malignancies in isolated tissue culture systems and in human clinical trials, but the duration of its effects has been transient. Recent evidence indicates that the basis for the limited duration of ATRA's activity, at least in one form of leukem...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(94)90040-x

    authors： Mehta K,Sadeghi T,McQueen T,Lopez-Berestein G

    更新日期：1994-08-01 00:00:00

  • Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia.

    abstract：:We have demonstrated that constitutive signal transducer and activator of transcription (STAT) 3 activity, observed in approximately 50% of acute myeloid leukemia (AML) cases, is associated with adverse treatment outcome. Constitutive STAT3 activation may result from the expression of oncogenic protein tyrosine kinase...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2007.11.035

    authors： Ghoshal Gupta S,Baumann H,Wetzler M

    更新日期：2008-07-01 00:00:00

  • Functional interleukin-2 receptor on a Tac negative human leukaemia T-cell line.

    abstract：:Cell line PER-423 was derived from the cells of a patient with an immature acute T-lymphoblastic leukaemia and the growth of this human cell line is strictly dependent on interleukin-2 (IL-2). PER-423 cells express the p75 (beta) subunit of the IL-2 receptor (IL-2R beta), while the p55 chain (IL-2R alpha) is not detec...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(93)90141-7

    authors： Kees UR,Ford J,Peroni SE,Ranford PR

    更新日期：1993-01-01 00:00:00

  • The nature of lysosomal enzyme glycosylation in ALL: relevance to abnormal beta-hexosaminidase expression.

    abstract：:The glycosylation of beta-hexosaminidase was investigated in the transformed cell-line, CCRF/CEM, derived from a human acute lymphoblastic leukaemia, and comparisons were made with enzyme from normal human skin fibroblasts. A series of studies including neuraminidase sensitivity, lectin chromatography, Biogel P4 chrom...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(88)90146-4

    authors： Moss SE,Besley GT

    更新日期：1988-01-01 00:00:00

  • Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.

    abstract：BACKGROUND:T- cell prolymphocytic leukemia (T- PLL) is a rare aggressive hematological malignancy. Alemtuzumab, an anti-CD52 humanized monoclonal antibody, is the treatment of choice for remission induction. Allogeneic hematopoietic cell transplantation (allo-HCT) has been described to induce durable remissions and imp...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2018.01.009

    authors： Dholaria BR,Ayala E,Sokol L,Nishihori T,Chavez JC,Hussaini M,Kumar A,Kharfan-Dabaja MA

    更新日期：2018-04-01 00:00:00

  • The demonstration of terminal deoxynucleotidyl transferase on frozen tissue sections and smears by the avidin-biotin complex (ABC) method.

    abstract：:A method using avidin-biotin complex (ABC) to detect the presence of the enzyme terminal deoxynucleotidyl transferase (TdT) is described and compared with a proven indirect immunofluorescence method. The material studied consisted of: (1) peripheral blood and bone marrow smears from 17 patients with leukemia (ALL, 8; ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(83)90107-8

    authors： Racklin B,Bearman R,Sheibani K,Winberg C,Rappaport H

    更新日期：1983-01-01 00:00:00

  • A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

    abstract：:Older patients with acute myelogenous leukemia (AML) have overexpression of P-glycoprotein (Pgp+), and this has been shown to correlate quantitatively with therapeutic outcome. Since Pgp-mediated efflux of cytotoxic drugs can be inhibited by the cyclosporine analogue, PSC 833, we investigated the use of this agent wit...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0145-2126(00)00024-2

    authors： Chauncey TR,Rankin C,Anderson JE,Chen I,Kopecky KJ,Godwin JE,Kalaycio ME,Moore DF,Shurafa MS,Petersdorf SH,Kraut EH,Leith CP,Head DR,Luthardt FW,Willman CL,Appelbaum FR

    更新日期：2000-07-01 00:00:00

  • Effect of thymosin and phorbol ester on purine metabolic enzymes and cell surface phenotype in a malignant T-cell line (MOLT-3).

    abstract：:Previous studies have shown that thymosin (fraction 5) is able to induce surface differentiation markers on normal murine bone marrow T-cell precursors. Phorbol ester (TPA) promotes differentiation of human leukaemic lymphoblasts as assessed by changes in phenotypic surface markers and terminal deoxynucleotidyl transf...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(83)90072-3

    authors： Ho AD,Ma DD,Price G,Hoffbrand AV

    更新日期：1983-01-01 00:00:00

  • Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2.

    abstract：:Although mutations in RNA splicing genes occur frequently in patients with clonal cytopenias of unknown significance (CCUS) and myelodysplastic syndromes (MDS), very often additional common myeloid gene driver mutations are present at diagnosis. Thus, the clinical significance of isolated mutations in the most commonl...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2017.09.002

    authors： Fleischman RA,Stockton SS,Cogle CR

    更新日期：2017-10-01 00:00:00

  • From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes.

    abstract：:A primary mitochondrial defect may be pivotal in the pathogenesis of acquired idiopathic sideroblastic anemia (AISA). The mitochondrial respiratory chain is involved in mitochondrial iron uptake and supply of ferrous iron (Fe2+) for heme synthesis. Mitochondrial DNA (mtDNA) comes into play because several subunits of ...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/s0145-2126(99)00160-5

    authors： Gattermann N

    更新日期：2000-02-01 00:00:00

  • A monoclonal antibody (SJ-9A4) to P24 present on common alls, neuroblastomas and platelets - I. Characterization and development of a unique radioimmunometric assay.

    abstract：:We report the development and characterization of SJ-9A4, a monoclonal antibody (MoAb) produced against common acute lymphoblastic leukemia (C-ALL) cell lines. SJ-9A4 reacted with C-ALL, B-cell chronic lymphocytic leukemia (B-CLL), platelets and C-ALL neuroblastoma (NB) and the K562 cell lines. It had no significant r...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(83)90044-9

    authors： Komada Y,Peiper SC,Melvin SL,Metzger DW,Tarnowski BH,Green AA

    更新日期：1983-01-01 00:00:00

  • HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells.

    abstract：:We analyzed the biological activity of HA14-1, a small organic compound inhibitor of Bcl-2, against established leukaemia cell lines and blasts from acute myeloid leukaemia (AML) patients. HA14-1 had a potent killing activity against the leukaemia cell line that expressed endogenous or ectopic Bcl-2. This activity was...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.11.010

    authors： Oliver L,Mahé B,Gréé R,Vallette FM,Juin P

    更新日期：2007-06-01 00:00:00

  • Modification of pentasaccharide core of surface N-glycans during differentiation of HL-60 cells.

    abstract：:All-trans retinoic acid (ATRA) or phorbol-12-myristate-13-acetate (PMA) are two representative inducers which induce the differentiation of HL-60 cells to myelocytes and monocytes respectively. Structural modifications of the pentasaccharide core portion of N-glycans on cell surface glycoproteins during differentiatio...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00068-x

    authors： Li Z,Liu AH,Liu F,Chen HL

    更新日期：1998-08-01 00:00:00

  • Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?

    abstract：:Fusion tyrosine kinases (FTKs) such as BCR/ABL, TEL/ABL, TEL/JAK2, TEL/PDGF beta R and NPM/ALK arise from reciprocal chromosomal translocations and cause acute and chronic myelogenous leukemias and non-Hodgkin's lymphoma. Murine hematopoietic growth factor dependent BaF3 cells and cells transformed by FTK (BaF3-FTK) w...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(02)00163-7

    authors： Hoser G,Majsterek I,Romana DL,Slupianek A,Blasiak J,Skorski T

    更新日期：2003-03-01 00:00:00

  • A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.

    abstract：:We designed a pharmacokinetic and pharmacodynamic phase I study of sequential topotecan (2.55-6.3mg/m2) by 72h infusion followed by five daily doses of etoposide for patients with refractory acute leukemia based upon synergistic anti-tumor activity of topoisomerase I and II inhibitors in vitro. Eight of the 29 patient...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0145-2126(02)00079-6

    authors： Cooper BW,Donaher E,Lazarus HM,Green SB,Gosky DM,Rosenthal NS,Berger SJ,Li X,Ingalls ST,Hoppel CL,Gerson SL

    更新日期：2003-01-01 00:00:00

  • Immunoglobulin G antibodies binding to a synthetic peptide deduced from the nucleotide sequence of the env gene of HTLV I in patients with leukemia and rheumatoid arthritis, HLA sensitized persons and blood donors.

    abstract：:A synthetic pentadecapeptide preparation, env 406-420, with an amino acid sequence deduced from the envelope glycoprotein gene of human T cell leukemia virus type I (HTLV I), was used as the antigen in an enzyme immunoassay for immunoglobulin G antibodies, exploring its usefulness for seroepidemiological purposes. The...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(85)90100-6

    authors： Blomberg J,Fölsch G,Nilsson I,Fäldt R

    更新日期：1985-01-01 00:00:00

  • Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C.

    abstract：:Thirty patients with high-risk myelodysplastic syndrome, defined as > 5% bone marrow blasts, were treated with a combination of oral all-trans-retinoic acid (45 mg/m2 daily) and subcutaneous AraC (10 mg/m2) on days 1-14 of each 28-35 day cycle repeated for 2-6 cycles. Complete remission lasting 9, 12, and 15 months wa...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0145-2126(99)00095-8

    authors： Letendre L,Noel P,White WL,Tefferi A,Litzow MR,Li CY,Schroeder G

    更新日期：1999-09-01 00:00:00